NIH RFA · NHLBI · K38
RFA-HL-27-010: Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The purpose of the Stimulating Access to Research in Residency Transition Scholar (StARRTS) K38 Career Development program is to retain and support clinician-investigators who have successfully completed the Stimulating Access to Research in Residency (StARR) R38 Program ( RFA-HL-26-012 and previous NOFOs) as resident-investigators. Individuals who receive K38 grants described in this Notice of Funding Opportunity (NOFO) will be referred to as Transition Scholars. The intent of this NOFO is to provide Transition Scholars with opportunities for additional research and career development during subsequent clinical fellowships or early career faculty appointments (as defined in Section III. 3.…
- NOFO number
- RFA-HL-27-010
- Type
- RFA
- Activity code
- K38
- Primary institute
- NHLBI · National Heart, Lung, and Blood Institute
- Clinical trials
- Not Allowed
- Posted
- Oct 9, 2026
- Opens
- Oct 9, 2026
- Expires
- Oct 14, 2028
RFA-HL-27-010 due dates
4 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| November 09, 2026 | November 09, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| June 11, 2027 | June 11, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 13, 2027 | October 13, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
| October 13, 2028 | October 13, 2028 | Not Applicable | March 2029 | May 2029 | July 2029 |
What its predecessor RFA-HL-23-007 funded
RFA-HL-27-010 reissues RFA-HL-23-007. Until awards appear under the new number, its funding history is the best guide to who wins under this program: 15 projects and $3.0M in FY2022–FY2026.
Projects funded
15
Distinct projects, FY2022–FY2026
New awards
15
Type 1 (new project) award records
NIH funding
$3.0M
Award dollars under RFA-HL-23-007, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 3 | 3 | $322K |
| FY2024 | 10 | 7 | $1.0M |
| FY2025 | 11 | 5 | $1.1M |
| FY2026 | 6 | 0 | $611K |
Institutions with the most funding
- Duke University$1.0M · 5 projects
- University of California, San Francisco$410K · 2 projects
- Emory University$291K · 1 project
- University of California Los Angeles$222K · 1 project
- Beth Israel Deaconess Medical Center$215K · 1 project
- University of Colorado Denver$213K · 1 project
- University of California at Davis$212K · 1 project
- Children's Hosp of Philadelphia$212K · 1 project
Funding institutes
- NHLBI$2.1M · 20
- NCI$517K · 6
- NIA$215K · 2
- NIAID$208K · 2
Activity codes funded
- K3830 records
Most recent new awards
- The Role of Rheology and Transfusion on Microvascular Thrombosis in Sepsis (opens NIH RePORTER)
Emory University · 1K38HL181374-01 · NHLBI · Notice Sep 12, 2025
$111KK38
- Epithelial cell mediated fibroblast activation through CTHRC1-TGFb signaling in fibrotic lung diseases (opens NIH RePORTER)
Duke University · 1K38HL180998-01 · NHLBI · Notice Sep 12, 2025
$108KK38
- The Role of Developmental Dysanapsis in Lung Development Throughout the Lifespan in Experimental Bronchopulmonary Dysplasia (opens NIH RePORTER)
University of Colorado Denver · 1K38HL180910-01 · NHLBI · Notice Sep 9, 2025
$106KK38
- Predictive Markers of Response to and Treatment Effects of Motixafortide, Cemiplimab, Gemcitabine and Nab-Paclitaxel in Treatment Naïve Metastatic Pancreatic Cancer (opens NIH RePORTER)
Columbia University Health Sciences · 1K38CA304069-01 · NCI · Notice Aug 11, 2025
$1K38
- Improving integration of treatment burden information in primary care for older adults with multiple chronic conditions (opens NIH RePORTER)
Beth Israel Deaconess Medical Center · 1K38AG094915-01 · NIA · Notice Aug 8, 2025
$107KK38
- Metabolic regulation of oxidative phosphorylation in pediatric AML relapse (opens NIH RePORTER)
Duke University · 1K38CA282963-01A1 · NCI · Notice Aug 26, 2024
$104KK38
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
3 NIH institutes and offices take applications under RFA-HL-27-010. Contact the program officer at the institute that fits your research before applying.
- NHLBI · National Heart, Lung, and Blood Institute
- NIAID · National Institute of Allergy and Infectious Diseases
- NCI · National Cancer Institute
Related notices
NIH lists no related notices for RFA-HL-27-010 yet.
Award terms
- Application types allowed
- New Resubmission Only those application types listed here are allowed for this NOFO. The OER Glossary and the How to Apply - Application Guide provides details on these application types.
- Award budget
- Information
- Project period
- The total project period may not exceed 2 years. Other
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.The following NIH components intend to commit the following amounts:NHLBI intends to commit total costs of up to 6,444,000 in FY 2027-2029 to support up to 6 new K38 awards per fiscal year.NIAID intends to commit up to 2,180,000 in total costs in FY 2027-2029 to support…
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of RFA-HL-23-007.
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.